The endocrinology of perimenopause: need for a paradigm shift.
Level 5 - mechanism / opinion, no new human data
Narrative review and expert opinion synthesizing existing cohort studies without systematic review methodology
PubMed 21196391 · doi:10.2741/s166
What was done
This narrative review synthesized endocrine and physiological literature—referencing longitudinal data from cohorts such as SWAN and the Tremin trust—to re-evaluate hormonal patterns and predictive biomarkers across the perimenopausal transition.
What was found
The author notes that approximately one-third of all perimenopausal cycles exhibit a major de novo estradiol surge during the luteal phase (termed a luteal out of phase [LOOP] event). Perimenopause is characterized by erratic, elevated estradiol levels, reduced progesterone production, and disrupted hypothalamic-pituitary-ovarian feedback. The abstract states that FSH and Inhibin B are ineffective for predicting proximity to menopause, while anti-Müllerian hormone may have predictive utility. No further quantitative values or statistical metrics are reported in the abstract.
Why it matters
This paper advocates shifting the clinical model of perimenopause away from simple estrogen deficiency toward an understanding driven by erratic estradiol spikes and relative progesterone deficits, impacting how midlife symptoms are managed.
Limits
As a narrative review, it lacks a systematic search protocol, study-level quality appraisal, and aggregated effect sizes. Total sample size and detailed numerical data are omitted from the abstract.
Cited by
- supports During perimenopause, progesterone is the first hormone to decline.